Esperion Announces The Company Plans To Highlight New Research Supporting Its Lead Development Candidates For The Treatment Of Primary Sclerosing Cholangitis April 24, 2025 Today At 9:00 AM ET In New York City. Also Expands Portfolio With Introduction Of A Novel Program Targeting PSC

– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC –

– Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models –

– Demonstrates Internal R&D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease –

– Esperion to Webcast R&D Day Event Today at 9:00 a.m. ET –

Esperion (NASDAQ:ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive liver disease, today at 9:00 a.m. ET in New York City. A live webcast of the event will also be available. These candidates are novel allosteric inhibitors of ATP citrate lyase (ACLY), a key metabolic enzyme with emerging relevance in hepatic inflammation and fibrosis.

"We are leveraging our deep expertise in ACLY biology to expand our portfolio beyond NEXLETOL® (bempedoic acid)/NEXLIZET® (bempedoic acid and ezetimibe) and to address the urgent needs of patients living with PSC," said Sheldon Koenig, Chief Executive Officer at Esperion. "Our lead candidates, including ESP-1336, are promising, potential first-in-class allosteric ACLY inhibitors, well-characterized with significant preclinical data, and represent a natural extension of our metabolic franchise. PSC is a rare and progressive liver disease with no approved therapies proven to slow or halt its progression. Our next-generation ACLY inhibitor discovery program was purpose-built to improve potency, selectivity, and guide indication and patient population selection through data-driven innovation."

"ACLY is a promising target in hepatic disease, given its central role in metabolic regulation," said David E. Cohen MD, PhD, Chief, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital. "By modulating acetyl-coenzyme A (acetyl-CoA) levels in multiple hepatobiliary cell types, these inhibitors may disrupt key disease-driving pathways in PSC, offering a potentially transformative approach to treatment."